mAbTree Biologics has signed an exclusive co-development and commercialisation partnership with Shilpa Biologicals (a fully owned subsidiary of Shilpa Medicare) for its novel biologic asset [a checkpoint inhibitor] for immuno-oncological applications.
Under the terms of the strategic agreement, Shilpa Biologicals will support both development – including clinical studies – as well as long-term commercial supply with GMP manufacturing. Additionally, Shilpa Group will provide mAbTree access to India and several global markets through its extensive partner network.
This programme aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation and generation of strong immune responses against tumours akin to the well-established PD-1/PD-L1 blockade. While PD-1/PD-L1 blockade has demonstrated remarkable clinical successes, recent studies suggest our novel target has a highly attractive therapeutic potential in various immuno-oncological states both as a monotherapy and combinatorial therapy. This approach has the potential to convert cold tumours (poor immune cell infiltration) hot (good immune infiltration), suppress tumour metastasis and make the refractory tumours susceptible to chemotherapy as well and is applicable in various cancers, including lung cancer, head and neck squamous cell carcinoma, and hematologic malignancies.
Shilpa Biologics will provide full-service capabilities from cell line development to GMP drug product manufacturing – with manufacturing and clinical supply conducted at its bio manufacturing facility at Dharwad, Karnataka.
mAbTree Biologics focuses on the development of innovative therapies for cancer and other life-threatening diseases. With a commitment to scientific excellence and patient care, mAbTree Biologics interdisciplinary team of scientists, clinicians, and researchers aims to transform the landscape of cancer treatment through research and development.